[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Oral GLP-1 Agonist Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

May 2024 | 70 pages | ID: G7B904444587EN
GlobalInfoResearch

US$ 3,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists can also help treat obesity. GLP-1 agonist medicines include injections and oral medications.

According to our (Global Info Research) latest study, the global Oral GLP-1 Agonist market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Oral GLP-1 Agonist market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Oral GLP-1 Agonist market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2019-2030

Global Oral GLP-1 Agonist market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2019-2030

Global Oral GLP-1 Agonist market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2019-2030

Global Oral GLP-1 Agonist market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Oral GLP-1 Agonist

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Oral GLP-1 Agonist market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Oral GLP-1 Agonist market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
  • Semaglutide
  • Non-peptide
Market segment by Application
  • Diabetes
  • Obesity
Major players covered
  • Novo Nordisk
  • Eli Lilly
Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Oral GLP-1 Agonist product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Oral GLP-1 Agonist, with price, sales quantity, revenue, and global market share of Oral GLP-1 Agonist from 2019 to 2024.

Chapter 3, the Oral GLP-1 Agonist competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Oral GLP-1 Agonist breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Oral GLP-1 Agonist market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Oral GLP-1 Agonist.

Chapter 14 and 15, to describe Oral GLP-1 Agonist sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
  1.3.1 Overview: Global Oral GLP-1 Agonist Consumption Value by Type: 2019 Versus 2023 Versus 2030
  1.3.2 Semaglutide
  1.3.3 Non-peptide
1.4 Market Analysis by Application
  1.4.1 Overview: Global Oral GLP-1 Agonist Consumption Value by Application: 2019 Versus 2023 Versus 2030
  1.4.2 Diabetes
  1.4.3 Obesity
1.5 Global Oral GLP-1 Agonist Market Size & Forecast
  1.5.1 Global Oral GLP-1 Agonist Consumption Value (2019 & 2023 & 2030)
  1.5.2 Global Oral GLP-1 Agonist Sales Quantity (2019-2030)
  1.5.3 Global Oral GLP-1 Agonist Average Price (2019-2030)

2 MANUFACTURERS PROFILES

2.1 Novo Nordisk
  2.1.1 Novo Nordisk Details
  2.1.2 Novo Nordisk Major Business
  2.1.3 Novo Nordisk Oral GLP-1 Agonist Product and Services
  2.1.4 Novo Nordisk Oral GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.1.5 Novo Nordisk Recent Developments/Updates
2.2 Eli Lilly
  2.2.1 Eli Lilly Details
  2.2.2 Eli Lilly Major Business
  2.2.3 Eli Lilly Oral GLP-1 Agonist Product and Services
  2.2.4 Eli Lilly Oral GLP-1 Agonist Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
  2.2.5 Eli Lilly Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: ORAL GLP-1 AGONIST BY MANUFACTURER

3.1 Global Oral GLP-1 Agonist Sales Quantity by Manufacturer (2019-2024)
3.2 Global Oral GLP-1 Agonist Revenue by Manufacturer (2019-2024)
3.3 Global Oral GLP-1 Agonist Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
  3.4.1 Producer Shipments of Oral GLP-1 Agonist by Manufacturer Revenue ($MM) and Market Share (%): 2023
  3.4.2 Top 3 Oral GLP-1 Agonist Manufacturer Market Share in 2023
  3.4.3 Top 6 Oral GLP-1 Agonist Manufacturer Market Share in 2023
3.5 Oral GLP-1 Agonist Market: Overall Company Footprint Analysis
  3.5.1 Oral GLP-1 Agonist Market: Region Footprint
  3.5.2 Oral GLP-1 Agonist Market: Company Product Type Footprint
  3.5.3 Oral GLP-1 Agonist Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Oral GLP-1 Agonist Market Size by Region
  4.1.1 Global Oral GLP-1 Agonist Sales Quantity by Region (2019-2030)
  4.1.2 Global Oral GLP-1 Agonist Consumption Value by Region (2019-2030)
  4.1.3 Global Oral GLP-1 Agonist Average Price by Region (2019-2030)
4.2 North America Oral GLP-1 Agonist Consumption Value (2019-2030)
4.3 Europe Oral GLP-1 Agonist Consumption Value (2019-2030)
4.4 Asia-Pacific Oral GLP-1 Agonist Consumption Value (2019-2030)
4.5 South America Oral GLP-1 Agonist Consumption Value (2019-2030)
4.6 Middle East & Africa Oral GLP-1 Agonist Consumption Value (2019-2030)

5 MARKET SEGMENT BY TYPE

5.1 Global Oral GLP-1 Agonist Sales Quantity by Type (2019-2030)
5.2 Global Oral GLP-1 Agonist Consumption Value by Type (2019-2030)
5.3 Global Oral GLP-1 Agonist Average Price by Type (2019-2030)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Oral GLP-1 Agonist Sales Quantity by Application (2019-2030)
6.2 Global Oral GLP-1 Agonist Consumption Value by Application (2019-2030)
6.3 Global Oral GLP-1 Agonist Average Price by Application (2019-2030)

7 NORTH AMERICA

7.1 North America Oral GLP-1 Agonist Sales Quantity by Type (2019-2030)
7.2 North America Oral GLP-1 Agonist Sales Quantity by Application (2019-2030)
7.3 North America Oral GLP-1 Agonist Market Size by Country
  7.3.1 North America Oral GLP-1 Agonist Sales Quantity by Country (2019-2030)
  7.3.2 North America Oral GLP-1 Agonist Consumption Value by Country (2019-2030)
  7.3.3 United States Market Size and Forecast (2019-2030)
  7.3.4 Canada Market Size and Forecast (2019-2030)
  7.3.5 Mexico Market Size and Forecast (2019-2030)

8 EUROPE

8.1 Europe Oral GLP-1 Agonist Sales Quantity by Type (2019-2030)
8.2 Europe Oral GLP-1 Agonist Sales Quantity by Application (2019-2030)
8.3 Europe Oral GLP-1 Agonist Market Size by Country
  8.3.1 Europe Oral GLP-1 Agonist Sales Quantity by Country (2019-2030)
  8.3.2 Europe Oral GLP-1 Agonist Consumption Value by Country (2019-2030)
  8.3.3 Germany Market Size and Forecast (2019-2030)
  8.3.4 France Market Size and Forecast (2019-2030)
  8.3.5 United Kingdom Market Size and Forecast (2019-2030)
  8.3.6 Russia Market Size and Forecast (2019-2030)
  8.3.7 Italy Market Size and Forecast (2019-2030)

9 ASIA-PACIFIC

9.1 Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Oral GLP-1 Agonist Market Size by Region
  9.3.1 Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Region (2019-2030)
  9.3.2 Asia-Pacific Oral GLP-1 Agonist Consumption Value by Region (2019-2030)
  9.3.3 China Market Size and Forecast (2019-2030)
  9.3.4 Japan Market Size and Forecast (2019-2030)
  9.3.5 South Korea Market Size and Forecast (2019-2030)
  9.3.6 India Market Size and Forecast (2019-2030)
  9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
  9.3.8 Australia Market Size and Forecast (2019-2030)

10 SOUTH AMERICA

10.1 South America Oral GLP-1 Agonist Sales Quantity by Type (2019-2030)
10.2 South America Oral GLP-1 Agonist Sales Quantity by Application (2019-2030)
10.3 South America Oral GLP-1 Agonist Market Size by Country
  10.3.1 South America Oral GLP-1 Agonist Sales Quantity by Country (2019-2030)
  10.3.2 South America Oral GLP-1 Agonist Consumption Value by Country (2019-2030)
  10.3.3 Brazil Market Size and Forecast (2019-2030)
  10.3.4 Argentina Market Size and Forecast (2019-2030)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Oral GLP-1 Agonist Market Size by Country
  11.3.1 Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Country (2019-2030)
  11.3.2 Middle East & Africa Oral GLP-1 Agonist Consumption Value by Country (2019-2030)
  11.3.3 Turkey Market Size and Forecast (2019-2030)
  11.3.4 Egypt Market Size and Forecast (2019-2030)
  11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
  11.3.6 South Africa Market Size and Forecast (2019-2030)

12 MARKET DYNAMICS

12.1 Oral GLP-1 Agonist Market Drivers
12.2 Oral GLP-1 Agonist Market Restraints
12.3 Oral GLP-1 Agonist Trends Analysis
12.4 Porters Five Forces Analysis
  12.4.1 Threat of New Entrants
  12.4.2 Bargaining Power of Suppliers
  12.4.3 Bargaining Power of Buyers
  12.4.4 Threat of Substitutes
  12.4.5 Competitive Rivalry

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Oral GLP-1 Agonist and Key Manufacturers
13.2 Manufacturing Costs Percentage of Oral GLP-1 Agonist
13.3 Oral GLP-1 Agonist Production Process
13.4 Industry Value Chain Analysis

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel
  14.1.1 Direct to End-User
  14.1.2 Distributors
14.2 Oral GLP-1 Agonist Typical Distributors
14.3 Oral GLP-1 Agonist Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

LIST OF TABLES

Table 1. Global Oral GLP-1 Agonist Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Oral GLP-1 Agonist Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 4. Novo Nordisk Major Business
Table 5. Novo Nordisk Oral GLP-1 Agonist Product and Services
Table 6. Novo Nordisk Oral GLP-1 Agonist Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Novo Nordisk Recent Developments/Updates
Table 8. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 9. Eli Lilly Major Business
Table 10. Eli Lilly Oral GLP-1 Agonist Product and Services
Table 11. Eli Lilly Oral GLP-1 Agonist Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Eli Lilly Recent Developments/Updates
Table 13. Global Oral GLP-1 Agonist Sales Quantity by Manufacturer (2019-2024) & (Units)
Table 14. Global Oral GLP-1 Agonist Revenue by Manufacturer (2019-2024) & (USD Million)
Table 15. Global Oral GLP-1 Agonist Average Price by Manufacturer (2019-2024) & (US$/Unit)
Table 16. Market Position of Manufacturers in Oral GLP-1 Agonist, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 17. Head Office and Oral GLP-1 Agonist Production Site of Key Manufacturer
Table 18. Oral GLP-1 Agonist Market: Company Product Type Footprint
Table 19. Oral GLP-1 Agonist Market: Company Product Application Footprint
Table 20. Oral GLP-1 Agonist New Market Entrants and Barriers to Market Entry
Table 21. Oral GLP-1 Agonist Mergers, Acquisition, Agreements, and Collaborations
Table 22. Global Oral GLP-1 Agonist Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
Table 23. Global Oral GLP-1 Agonist Sales Quantity by Region (2019-2024) & (Units)
Table 24. Global Oral GLP-1 Agonist Sales Quantity by Region (2025-2030) & (Units)
Table 25. Global Oral GLP-1 Agonist Consumption Value by Region (2019-2024) & (USD Million)
Table 26. Global Oral GLP-1 Agonist Consumption Value by Region (2025-2030) & (USD Million)
Table 27. Global Oral GLP-1 Agonist Average Price by Region (2019-2024) & (US$/Unit)
Table 28. Global Oral GLP-1 Agonist Average Price by Region (2025-2030) & (US$/Unit)
Table 29. Global Oral GLP-1 Agonist Sales Quantity by Type (2019-2024) & (Units)
Table 30. Global Oral GLP-1 Agonist Sales Quantity by Type (2025-2030) & (Units)
Table 31. Global Oral GLP-1 Agonist Consumption Value by Type (2019-2024) & (USD Million)
Table 32. Global Oral GLP-1 Agonist Consumption Value by Type (2025-2030) & (USD Million)
Table 33. Global Oral GLP-1 Agonist Average Price by Type (2019-2024) & (US$/Unit)
Table 34. Global Oral GLP-1 Agonist Average Price by Type (2025-2030) & (US$/Unit)
Table 35. Global Oral GLP-1 Agonist Sales Quantity by Application (2019-2024) & (Units)
Table 36. Global Oral GLP-1 Agonist Sales Quantity by Application (2025-2030) & (Units)
Table 37. Global Oral GLP-1 Agonist Consumption Value by Application (2019-2024) & (USD Million)
Table 38. Global Oral GLP-1 Agonist Consumption Value by Application (2025-2030) & (USD Million)
Table 39. Global Oral GLP-1 Agonist Average Price by Application (2019-2024) & (US$/Unit)
Table 40. Global Oral GLP-1 Agonist Average Price by Application (2025-2030) & (US$/Unit)
Table 41. North America Oral GLP-1 Agonist Sales Quantity by Type (2019-2024) & (Units)
Table 42. North America Oral GLP-1 Agonist Sales Quantity by Type (2025-2030) & (Units)
Table 43. North America Oral GLP-1 Agonist Sales Quantity by Application (2019-2024) & (Units)
Table 44. North America Oral GLP-1 Agonist Sales Quantity by Application (2025-2030) & (Units)
Table 45. North America Oral GLP-1 Agonist Sales Quantity by Country (2019-2024) & (Units)
Table 46. North America Oral GLP-1 Agonist Sales Quantity by Country (2025-2030) & (Units)
Table 47. North America Oral GLP-1 Agonist Consumption Value by Country (2019-2024) & (USD Million)
Table 48. North America Oral GLP-1 Agonist Consumption Value by Country (2025-2030) & (USD Million)
Table 49. Europe Oral GLP-1 Agonist Sales Quantity by Type (2019-2024) & (Units)
Table 50. Europe Oral GLP-1 Agonist Sales Quantity by Type (2025-2030) & (Units)
Table 51. Europe Oral GLP-1 Agonist Sales Quantity by Application (2019-2024) & (Units)
Table 52. Europe Oral GLP-1 Agonist Sales Quantity by Application (2025-2030) & (Units)
Table 53. Europe Oral GLP-1 Agonist Sales Quantity by Country (2019-2024) & (Units)
Table 54. Europe Oral GLP-1 Agonist Sales Quantity by Country (2025-2030) & (Units)
Table 55. Europe Oral GLP-1 Agonist Consumption Value by Country (2019-2024) & (USD Million)
Table 56. Europe Oral GLP-1 Agonist Consumption Value by Country (2025-2030) & (USD Million)
Table 57. Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Type (2019-2024) & (Units)
Table 58. Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Type (2025-2030) & (Units)
Table 59. Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Application (2019-2024) & (Units)
Table 60. Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Application (2025-2030) & (Units)
Table 61. Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Region (2019-2024) & (Units)
Table 62. Asia-Pacific Oral GLP-1 Agonist Sales Quantity by Region (2025-2030) & (Units)
Table 63. Asia-Pacific Oral GLP-1 Agonist Consumption Value by Region (2019-2024) & (USD Million)
Table 64. Asia-Pacific Oral GLP-1 Agonist Consumption Value by Region (2025-2030) & (USD Million)
Table 65. South America Oral GLP-1 Agonist Sales Quantity by Type (2019-2024) & (Units)
Table 66. South America Oral GLP-1 Agonist Sales Quantity by Type (2025-2030) & (Units)
Table 67. South America Oral GLP-1 Agonist Sales Quantity by Application (2019-2024) & (Units)
Table 68. South America Oral GLP-1 Agonist Sales Quantity by Application (2025-2030) & (Units)
Table 69. South America Oral GLP-1 Agonist Sales Quantity by Country (2019-2024) & (Units)
Table 70. South America Oral GLP-1 Agonist Sales Quantity by Country (2025-2030) & (Units)
Table 71. South America Oral GLP-1 Agonist Consumption Value by Country (2019-2024) & (USD Million)
Table 72. South America Oral GLP-1 Agonist Consumption Value by Country (2025-2030) & (USD Million)
Table 73. Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Type (2019-2024) & (Units)
Table 74. Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Type (2025-2030) & (Units)
Table 75. Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Application (2019-2024) & (Units)
Table 76. Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Application (2025-2030) & (Units)
Table 77. Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Country (2019-2024) & (Units)
Table 78. Middle East & Africa Oral GLP-1 Agonist Sales Quantity by Country (2025-2030) & (Units)
Table 79. Middle East & Africa Oral GLP-1 Agonist Consumption Value by Country (2019-2024) & (USD Million)
Table 80. Middle East & Africa Oral GLP-1 Agonist Consumption Value by Country (2025-2030) & (USD Million)
Table 81. Oral GLP-1 Agonist Raw Material
Table 82. Key Manufacturers of Oral GLP-1 Agonist Raw Materials
Table 83. Oral GLP-1 Agonist Typical Distributors
Table 84. Oral GLP-1 Agonist Typical Customers
List of Figures
Figure 1. Oral GLP-1 Agonist Picture
Figure 2. Global Oral GLP-1 Agonist Revenue by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Oral GLP-1 Agonist Revenue Market Share by Type in 2023
Figure 4. Semaglutide Examples
Figure 5. Non-peptide Examples
Figure 6. Global Oral GLP-1 Agonist Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 7. Global Oral GLP-1 Agonist Revenue Market Share by Application in 2023
Figure 8. Diabetes Examples
Figure 9. Obesity Examples
Figure 10. Global Oral GLP-1 Agonist Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global Oral GLP-1 Agonist Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Oral GLP-1 Agonist Sales Quantity (2019-2030) & (Units)
Figure 13. Global Oral GLP-1 Agonist Price (2019-2030) & (US$/Unit)
Figure 14. Global Oral GLP-1 Agonist Sales Quantity Market Share by Manufacturer in 2023
Figure 15. Global Oral GLP-1 Agonist Revenue Market Share by Manufacturer in 2023
Figure 16. Producer Shipments of Oral GLP-1 Agonist by Manufacturer Sales ($MM) and Market Share (%): 2023
Figure 17. Top 3 Oral GLP-1 Agonist Manufacturer (Revenue) Market Share in 2023
Figure 18. Top 6 Oral GLP-1 Agonist Manufacturer (Revenue) Market Share in 2023
Figure 19. Global Oral GLP-1 Agonist Sales Quantity Market Share by Region (2019-2030)
Figure 20. Global Oral GLP-1 Agonist Consumption Value Market Share by Region (2019-2030)
Figure 21. North America Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 22. Europe Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 23. Asia-Pacific Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 24. South America Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 25. Middle East & Africa Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 26. Global Oral GLP-1 Agonist Sales Quantity Market Share by Type (2019-2030)
Figure 27. Global Oral GLP-1 Agonist Consumption Value Market Share by Type (2019-2030)
Figure 28. Global Oral GLP-1 Agonist Average Price by Type (2019-2030) & (US$/Unit)
Figure 29. Global Oral GLP-1 Agonist Sales Quantity Market Share by Application (2019-2030)
Figure 30. Global Oral GLP-1 Agonist Revenue Market Share by Application (2019-2030)
Figure 31. Global Oral GLP-1 Agonist Average Price by Application (2019-2030) & (US$/Unit)
Figure 32. North America Oral GLP-1 Agonist Sales Quantity Market Share by Type (2019-2030)
Figure 33. North America Oral GLP-1 Agonist Sales Quantity Market Share by Application (2019-2030)
Figure 34. North America Oral GLP-1 Agonist Sales Quantity Market Share by Country (2019-2030)
Figure 35. North America Oral GLP-1 Agonist Consumption Value Market Share by Country (2019-2030)
Figure 36. United States Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 37. Canada Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 38. Mexico Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 39. Europe Oral GLP-1 Agonist Sales Quantity Market Share by Type (2019-2030)
Figure 40. Europe Oral GLP-1 Agonist Sales Quantity Market Share by Application (2019-2030)
Figure 41. Europe Oral GLP-1 Agonist Sales Quantity Market Share by Country (2019-2030)
Figure 42. Europe Oral GLP-1 Agonist Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 44. France Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Oral GLP-1 Agonist Sales Quantity Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Oral GLP-1 Agonist Sales Quantity Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Oral GLP-1 Agonist Sales Quantity Market Share by Region (2019-2030)
Figure 51. Asia-Pacific Oral GLP-1 Agonist Consumption Value Market Share by Region (2019-2030)
Figure 52. China Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 53. Japan Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 54. South Korea Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 55. India Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 56. Southeast Asia Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 57. Australia Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 58. South America Oral GLP-1 Agonist Sales Quantity Market Share by Type (2019-2030)
Figure 59. South America Oral GLP-1 Agonist Sales Quantity Market Share by Application (2019-2030)
Figure 60. South America Oral GLP-1 Agonist Sales Quantity Market Share by Country (2019-2030)
Figure 61. South America Oral GLP-1 Agonist Consumption Value Market Share by Country (2019-2030)
Figure 62. Brazil Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 63. Argentina Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 64. Middle East & Africa Oral GLP-1 Agonist Sales Quantity Market Share by Type (2019-2030)
Figure 65. Middle East & Africa Oral GLP-1 Agonist Sales Quantity Market Share by Application (2019-2030)
Figure 66. Middle East & Africa Oral GLP-1 Agonist Sales Quantity Market Share by Country (2019-2030)
Figure 67. Middle East & Africa Oral GLP-1 Agonist Consumption Value Market Share by Country (2019-2030)
Figure 68. Turkey Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 69. Egypt Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 70. Saudi Arabia Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 71. South Africa Oral GLP-1 Agonist Consumption Value (2019-2030) & (USD Million)
Figure 72. Oral GLP-1 Agonist Market Drivers
Figure 73. Oral GLP-1 Agonist Market Restraints
Figure 74. Oral GLP-1 Agonist Market Trends
Figure 75. Porters Five Forces Analysis
Figure 76. Manufacturing Cost Structure Analysis of Oral GLP-1 Agonist in 2023
Figure 77. Manufacturing Process Analysis of Oral GLP-1 Agonist
Figure 78. Oral GLP-1 Agonist Industrial Chain
Figure 79. Sales Channel: Direct to End-User vs Distributors
Figure 80. Direct Channel Pros & Cons
Figure 81. Indirect Channel Pros & Cons
Figure 82. Methodology
Figure 83. Research Process and Data Source


More Publications